Skip to main content
Erschienen in: Virchows Archiv 1/2014

01.01.2014 | Original Article

Increased Toll-like receptor 5 expression indicates esophageal columnar dysplasia

verfasst von: Olli Helminen, Heikki Huhta, Heikki Takala, Petri P. Lehenkari, Juha Saarnio, Joonas H. Kauppila, Tuomo J. Karttunen

Erschienen in: Virchows Archiv | Ausgabe 1/2014

Einloggen, um Zugang zu erhalten

Abstract

Toll-like receptor 5 (TLR5) is an immune receptor, which recognizes bacterial flagellin. Increased expression has been reported in various premalignant and malignant lesions indicating a role in carcinogenesis. We assessed the expression of TLR5 in normal esophageal squamous epithelium, Barrett’s esophagus with and without dysplasia, and in esophageal adenocarcinoma. Specimens with normal esophagus (n = 93), gastric (n = 75) or intestinal metaplasia (n = 53) without dysplasia, and low-grade (n = 56) or high-grade dysplasia (n = 33) and esophageal adenocarcinoma (n = 94) were studied. TLR5 immunohistochemical stainings were analyzed for the proportion of positive cells and the intensity of expression. In normal squamous epithelium, only the basal third showed TLR5 expression. In esophageal gastric or intestinal metaplasia, expression was present in majority of the cells but significantly weaker (p < 0.001) than in dysplastic epithelium. In dysplasia, expression extended to the apical cytoplasm, contrasting basolateral expression in non-dysplastic columnar epithelium. Receiver operating characteristic curve analysis showed that moderate to high expression intensity of TLR5 indicates low-grade dysplasia with 86 % sensitivity and 83 % specificity. Carcinomas showed increased expression in comparison with non-dysplastic columnar epithelium, but there was no association with prognosis. Our results indicate that the esophageal columnar dysplasia is associated with clear increase of TLR5 expression and dissolution of regular polarized expression. TLR5 staining provides a possible biomarker for the recognition of low-grade dysplasia. In addition, the findings suggest a role for abnormal expression of TLR5 in the pathogenesis of esophageal adenocarcinoma and suggest importance of altered microbiome in the pathogenesis of complications of Barrett’s esophagus.
Literatur
2.
Zurück zum Zitat Kumar H, Kawai T, Akira S (2011) Pathogen recognition by the innate immune system. Int Rev Immunol 30:16–34PubMedCrossRef Kumar H, Kawai T, Akira S (2011) Pathogen recognition by the innate immune system. Int Rev Immunol 30:16–34PubMedCrossRef
4.
5.
Zurück zum Zitat Liew FY, Xu D, Brint EK, O’Neill LA (2005) Negative regulation of Toll-like receptor-mediated immune responses. Nat Rev Immunol 5:446–458PubMedCrossRef Liew FY, Xu D, Brint EK, O’Neill LA (2005) Negative regulation of Toll-like receptor-mediated immune responses. Nat Rev Immunol 5:446–458PubMedCrossRef
6.
Zurück zum Zitat Huang B, Zhao J, Li H, He KL, Chen Y, Chen SH, Mayer L, Unkeless JC, Xiong H (2005) Toll-like receptors on tumor cells facilitate evasion of immune surveillance. Cancer Res 65:5009–5014PubMedCrossRef Huang B, Zhao J, Li H, He KL, Chen Y, Chen SH, Mayer L, Unkeless JC, Xiong H (2005) Toll-like receptors on tumor cells facilitate evasion of immune surveillance. Cancer Res 65:5009–5014PubMedCrossRef
7.
Zurück zum Zitat Pimentel-Nunes P, Afonso L, Lopes P, Roncon-Albuquerque R Jr, Goncalves N, Henrique R, Moreira-Dias L, Leite-Moreira AF, Dinis-Ribeiro M (2011) Increased expression of Toll-like receptors (TLR) 2, 4 and 5 in gastric dysplasia. Pathol Oncol Res 17:677–683PubMedCrossRef Pimentel-Nunes P, Afonso L, Lopes P, Roncon-Albuquerque R Jr, Goncalves N, Henrique R, Moreira-Dias L, Leite-Moreira AF, Dinis-Ribeiro M (2011) Increased expression of Toll-like receptors (TLR) 2, 4 and 5 in gastric dysplasia. Pathol Oncol Res 17:677–683PubMedCrossRef
8.
Zurück zum Zitat Kauppila JH, Takala H, Selander KS, Lehenkari PP, Saarnio J, Karttunen TJ (2011) Increased Toll-like receptor 9 expression indicates adverse prognosis in oesophageal adenocarcinoma. Histopathology 59:643–649PubMedCrossRef Kauppila JH, Takala H, Selander KS, Lehenkari PP, Saarnio J, Karttunen TJ (2011) Increased Toll-like receptor 9 expression indicates adverse prognosis in oesophageal adenocarcinoma. Histopathology 59:643–649PubMedCrossRef
9.
Zurück zum Zitat Hayashi F, Smith KD, Ozinsky A, Hawn TR, Yi EC, Goodlett DR, Eng JK, Akira S, Underhill DM, Aderem A (2001) The innate immune response to bacterial flagellin is mediated by Toll-like receptor 5. Nature 410:1099–1103PubMedCrossRef Hayashi F, Smith KD, Ozinsky A, Hawn TR, Yi EC, Goodlett DR, Eng JK, Akira S, Underhill DM, Aderem A (2001) The innate immune response to bacterial flagellin is mediated by Toll-like receptor 5. Nature 410:1099–1103PubMedCrossRef
10.
Zurück zum Zitat Schmausser B, Andrulis M, Endrich S, Lee SK, Josenhans C, Muller-Hermelink HK, Eck M (2004) Expression and subcellular distribution of Toll-like receptors TLR4, TLR5 and TLR9 on the gastric epithelium in Helicobacter pylori infection. Clin Exp Immunol 136:521–526PubMedCentralPubMed Schmausser B, Andrulis M, Endrich S, Lee SK, Josenhans C, Muller-Hermelink HK, Eck M (2004) Expression and subcellular distribution of Toll-like receptors TLR4, TLR5 and TLR9 on the gastric epithelium in Helicobacter pylori infection. Clin Exp Immunol 136:521–526PubMedCentralPubMed
11.
Zurück zum Zitat Park JH, Yoon HE, Kim DJ, Kim SA, Ahn SG, Yoon JH (2011) Toll-like receptor 5 activation promotes migration and invasion of salivary gland adenocarcinoma. J Oral Pathol Med 40:187–193PubMedCrossRef Park JH, Yoon HE, Kim DJ, Kim SA, Ahn SG, Yoon JH (2011) Toll-like receptor 5 activation promotes migration and invasion of salivary gland adenocarcinoma. J Oral Pathol Med 40:187–193PubMedCrossRef
12.
Zurück zum Zitat Kauppila JH, Mattila AE, Karttunen TJ, Salo T (2013) Toll-like receptor 5 (TLR5) expression is a novel predictive marker for recurrence and survival in squamous cell carcinoma of the tongue. Br J Cancer 108(3):638–43PubMedCrossRef Kauppila JH, Mattila AE, Karttunen TJ, Salo T (2013) Toll-like receptor 5 (TLR5) expression is a novel predictive marker for recurrence and survival in squamous cell carcinoma of the tongue. Br J Cancer 108(3):638–43PubMedCrossRef
13.
Zurück zum Zitat Jones RM, Sloane VM, Wu H, Luo L, Kumar A, Kumar MV, Gewirtz AT, Neish AS (2011) Flagellin administration protects gut mucosal tissue from irradiation-induced apoptosis via MKP-7 activity. Gut 60:648–657PubMedCrossRef Jones RM, Sloane VM, Wu H, Luo L, Kumar A, Kumar MV, Gewirtz AT, Neish AS (2011) Flagellin administration protects gut mucosal tissue from irradiation-induced apoptosis via MKP-7 activity. Gut 60:648–657PubMedCrossRef
14.
Zurück zum Zitat Kim WY, Lee JW, Choi JJ, Choi CH, Kim TJ, Kim BG, Song SY, Bae DS (2008) Increased expression of Toll-like receptor 5 during progression of cervical neoplasia. Int J Gynecol Cancer 18:300–305PubMedCrossRef Kim WY, Lee JW, Choi JJ, Choi CH, Kim TJ, Kim BG, Song SY, Bae DS (2008) Increased expression of Toll-like receptor 5 during progression of cervical neoplasia. Int J Gynecol Cancer 18:300–305PubMedCrossRef
15.
Zurück zum Zitat Pohl H, Welch HG (2005) The role of overdiagnosis and reclassification in the marked increase of esophageal adenocarcinoma incidence. J Natl Cancer Inst 97:142–146PubMedCrossRef Pohl H, Welch HG (2005) The role of overdiagnosis and reclassification in the marked increase of esophageal adenocarcinoma incidence. J Natl Cancer Inst 97:142–146PubMedCrossRef
16.
Zurück zum Zitat Pei Z, Bini EJ, Yang L, Zhou M, Francois F, Blaser MJ (2004) Bacterial biota in the human distal esophagus. Proc Natl Acad Sci U S A 101:4250–4255PubMedCentralPubMedCrossRef Pei Z, Bini EJ, Yang L, Zhou M, Francois F, Blaser MJ (2004) Bacterial biota in the human distal esophagus. Proc Natl Acad Sci U S A 101:4250–4255PubMedCentralPubMedCrossRef
17.
Zurück zum Zitat Yang L, Lu X, Nossa CW, Francois F, Peek RM, Pei Z (2009) Inflammation and intestinal metaplasia of the distal esophagus are associated with alterations in the microbiome. Gastroenterology 137:588–597PubMedCentralPubMedCrossRef Yang L, Lu X, Nossa CW, Francois F, Peek RM, Pei Z (2009) Inflammation and intestinal metaplasia of the distal esophagus are associated with alterations in the microbiome. Gastroenterology 137:588–597PubMedCentralPubMedCrossRef
18.
Zurück zum Zitat Pei Z, Yang L, Peek RM Jr, Levine SM, Pride DT, Blaser MJ (2005) Bacterial biota in reflux esophagitis and Barrett’s esophagus. World J Gastroenterol 11:7277–7283PubMedCentralPubMed Pei Z, Yang L, Peek RM Jr, Levine SM, Pride DT, Blaser MJ (2005) Bacterial biota in reflux esophagitis and Barrett’s esophagus. World J Gastroenterol 11:7277–7283PubMedCentralPubMed
19.
Zurück zum Zitat Odze RD (2009) Barrett esophagus: histology and pathology for the clinician. Nat Rev Gastroenterol Hepatol 6:478–490PubMedCrossRef Odze RD (2009) Barrett esophagus: histology and pathology for the clinician. Nat Rev Gastroenterol Hepatol 6:478–490PubMedCrossRef
20.
Zurück zum Zitat Reid BJ, Haggitt RC, Rubin CE, Roth G, Surawicz CM, Van Belle G, Lewin K, Weinstein WM, Antonioli DA, Goldman H (1988) Observer variation in the diagnosis of dysplasia in Barrett’s esophagus. Hum Pathol 19:166–178PubMedCrossRef Reid BJ, Haggitt RC, Rubin CE, Roth G, Surawicz CM, Van Belle G, Lewin K, Weinstein WM, Antonioli DA, Goldman H (1988) Observer variation in the diagnosis of dysplasia in Barrett’s esophagus. Hum Pathol 19:166–178PubMedCrossRef
21.
Zurück zum Zitat Baker BS, Ovigne JM, Powles AV, Corcoran S, Fry L (2003) Normal keratinocytes express Toll-like receptors (TLRs) 1, 2 and 5: modulation of TLR expression in chronic plaque psoriasis. Br J Dermatol 148:670–679PubMedCrossRef Baker BS, Ovigne JM, Powles AV, Corcoran S, Fry L (2003) Normal keratinocytes express Toll-like receptors (TLRs) 1, 2 and 5: modulation of TLR expression in chronic plaque psoriasis. Br J Dermatol 148:670–679PubMedCrossRef
22.
Zurück zum Zitat Takala H, Kauppila JH, Soini Y, Selander KS, Vuopala KS, Lehenkari PP, Saarnio J, Karttunen TJ (2011) Toll-like receptor 9 is a novel biomarker for esophageal squamous cell dysplasia and squamous cell carcinoma progression. J Innate Immun 3:631–638PubMedCrossRef Takala H, Kauppila JH, Soini Y, Selander KS, Vuopala KS, Lehenkari PP, Saarnio J, Karttunen TJ (2011) Toll-like receptor 9 is a novel biomarker for esophageal squamous cell dysplasia and squamous cell carcinoma progression. J Innate Immun 3:631–638PubMedCrossRef
23.
Zurück zum Zitat Yang L, Francois F, Pei Z (2012) Molecular pathways: pathogenesis and clinical implications of microbiome alteration in esophagitis and Barrett esophagus. Clin Cancer Res 18:2138–2144PubMedCentralPubMedCrossRef Yang L, Francois F, Pei Z (2012) Molecular pathways: pathogenesis and clinical implications of microbiome alteration in esophagitis and Barrett esophagus. Clin Cancer Res 18:2138–2144PubMedCentralPubMedCrossRef
24.
Zurück zum Zitat Mullin JM, Valenzano MC, Trembeth S, Allegretti PD, Verrecchio JJ, Schmidt JD, Jain V, Meddings JB, Mercogliano G, Thornton JJ (2006) Transepithelial leak in Barrett’s esophagus. Dig Dis Sci 51:2326–2336PubMedCrossRef Mullin JM, Valenzano MC, Trembeth S, Allegretti PD, Verrecchio JJ, Schmidt JD, Jain V, Meddings JB, Mercogliano G, Thornton JJ (2006) Transepithelial leak in Barrett’s esophagus. Dig Dis Sci 51:2326–2336PubMedCrossRef
25.
Zurück zum Zitat Ormsby AH, Petras RE, Henricks WH, Rice TW, Rybicki LA, Richter JE, Goldblum JR (2002) Observer variation in the diagnosis of superficial oesophageal adenocarcinoma. Gut 51:671–676PubMedCrossRef Ormsby AH, Petras RE, Henricks WH, Rice TW, Rybicki LA, Richter JE, Goldblum JR (2002) Observer variation in the diagnosis of superficial oesophageal adenocarcinoma. Gut 51:671–676PubMedCrossRef
26.
Zurück zum Zitat Kerkhof M, van Dekken H, Steyerberg EW, Meijer GA, Mulder AH, de Bruine A, Driessen A, ten Kate FJ, Kusters JG, Kuipers EJ, Siersema PD, CYBAR study group (2007) Grading of dysplasia in Barrett’s oesophagus: substantial interobserver variation between general and gastrointestinal pathologists. Histopathology 50:920–927CrossRef Kerkhof M, van Dekken H, Steyerberg EW, Meijer GA, Mulder AH, de Bruine A, Driessen A, ten Kate FJ, Kusters JG, Kuipers EJ, Siersema PD, CYBAR study group (2007) Grading of dysplasia in Barrett’s oesophagus: substantial interobserver variation between general and gastrointestinal pathologists. Histopathology 50:920–927CrossRef
27.
Zurück zum Zitat Curvers WL, ten Kate FJ, Krishnadath KK, Visser M, Elzer B, Baak LC, Bohmer C, Mallant-Hent RC, van Oijen A, Naber AH, Scholten P, Busch OR, Blaauwgeers HG, Meijer GA, Bergman JJ (2010) Low-grade dysplasia in Barrett’s esophagus: overdiagnosed and underestimated. Am J Gastroenterol 105:1523–1530PubMedCrossRef Curvers WL, ten Kate FJ, Krishnadath KK, Visser M, Elzer B, Baak LC, Bohmer C, Mallant-Hent RC, van Oijen A, Naber AH, Scholten P, Busch OR, Blaauwgeers HG, Meijer GA, Bergman JJ (2010) Low-grade dysplasia in Barrett’s esophagus: overdiagnosed and underestimated. Am J Gastroenterol 105:1523–1530PubMedCrossRef
28.
Zurück zum Zitat Skacel M, Petras RE, Gramlich TL, Sigel JE, Richter JE, Goldblum JR (2000) The diagnosis of low-grade dysplasia in Barrett’s esophagus and its implications for disease progression. Am J Gastroenterol 95:3383–3387PubMedCrossRef Skacel M, Petras RE, Gramlich TL, Sigel JE, Richter JE, Goldblum JR (2000) The diagnosis of low-grade dysplasia in Barrett’s esophagus and its implications for disease progression. Am J Gastroenterol 95:3383–3387PubMedCrossRef
29.
Zurück zum Zitat Srivastava A, Hornick JL, Li X, Blount PL, Sanchez CA, Cowan DS, Ayub K, Maley CC, Reid BJ, Odze RD (2007) Extent of low-grade dysplasia is a risk factor for the development of esophageal adenocarcinoma in Barrett’s esophagus. Am J Gastroenterol 102:483–493, quiz 694PubMedCrossRef Srivastava A, Hornick JL, Li X, Blount PL, Sanchez CA, Cowan DS, Ayub K, Maley CC, Reid BJ, Odze RD (2007) Extent of low-grade dysplasia is a risk factor for the development of esophageal adenocarcinoma in Barrett’s esophagus. Am J Gastroenterol 102:483–493, quiz 694PubMedCrossRef
30.
Zurück zum Zitat Bennett C, Vakil N, Bergman J, Harrison R, Odze R, Vieth M, Sanders S, Gay L, Pech O, Longcroft-Wheaton G, Romero Y, Inadomi J, Tack J, Corley DA, Manner H, Green S, Al Dulaimi D, Ali H, Allum B, Anderson M, Curtis H, Falk G, Fennerty MB, Fullarton G, Krishnadath K, Meltzer SJ, Armstrong D, Ganz R, Cengia G, Going JJ, Goldblum J, Gordon C, Grabsch H, Haigh C, Hongo M, Johnston D, Forbes-Young R, Kay E, Kaye P, Lerut T, Lovat LB, Lundell L, Mairs P, Shimoda T, Spechler S, Sontag S, Malfertheiner P, Murray I, Nanji M, Poller D, Ragunath K, Regula J, Cestari R, Shepherd N, Singh R, Stein HJ, Talley NJ, Galmiche JP, Tham TC, Watson P, Yerian L, Rugge M, Rice TW, Hart J, Gittens S, Hewin D, Hochberger J, Kahrilas P, Preston S, Sampliner R, Sharma P, Stuart R, Wang K, Waxman I, Abley C, Loft D, Penman I, Shaheen NJ, Chak A, Davies G, Dunn L, Falck-Ytter Y, Decaestecker J, Bhandari P, Ell C, Griffin SM, Attwood S, Barr H, Allen J, Ferguson MK, Moayyedi P, Jankowski JA (2012) Consensus statements for management of Barrett’s dysplasia and early-stage esophageal adenocarcinoma, based on a Delphi process. Gastroenterology 143:336–346PubMedCrossRef Bennett C, Vakil N, Bergman J, Harrison R, Odze R, Vieth M, Sanders S, Gay L, Pech O, Longcroft-Wheaton G, Romero Y, Inadomi J, Tack J, Corley DA, Manner H, Green S, Al Dulaimi D, Ali H, Allum B, Anderson M, Curtis H, Falk G, Fennerty MB, Fullarton G, Krishnadath K, Meltzer SJ, Armstrong D, Ganz R, Cengia G, Going JJ, Goldblum J, Gordon C, Grabsch H, Haigh C, Hongo M, Johnston D, Forbes-Young R, Kay E, Kaye P, Lerut T, Lovat LB, Lundell L, Mairs P, Shimoda T, Spechler S, Sontag S, Malfertheiner P, Murray I, Nanji M, Poller D, Ragunath K, Regula J, Cestari R, Shepherd N, Singh R, Stein HJ, Talley NJ, Galmiche JP, Tham TC, Watson P, Yerian L, Rugge M, Rice TW, Hart J, Gittens S, Hewin D, Hochberger J, Kahrilas P, Preston S, Sampliner R, Sharma P, Stuart R, Wang K, Waxman I, Abley C, Loft D, Penman I, Shaheen NJ, Chak A, Davies G, Dunn L, Falck-Ytter Y, Decaestecker J, Bhandari P, Ell C, Griffin SM, Attwood S, Barr H, Allen J, Ferguson MK, Moayyedi P, Jankowski JA (2012) Consensus statements for management of Barrett’s dysplasia and early-stage esophageal adenocarcinoma, based on a Delphi process. Gastroenterology 143:336–346PubMedCrossRef
31.
Zurück zum Zitat Cai Z, Sanchez A, Shi Z, Zhang T, Liu M, Zhang D (2011) Activation of Toll-like receptor 5 on breast cancer cells by flagellin suppresses cell proliferation and tumor growth. Cancer Res 71:2466–2475PubMedCentralPubMedCrossRef Cai Z, Sanchez A, Shi Z, Zhang T, Liu M, Zhang D (2011) Activation of Toll-like receptor 5 on breast cancer cells by flagellin suppresses cell proliferation and tumor growth. Cancer Res 71:2466–2475PubMedCentralPubMedCrossRef
32.
Zurück zum Zitat Rhee SH, Im E, Pothoulakis C (2008) Toll-like receptor 5 engagement modulates tumor development and growth in a mouse xenograft model of human colon cancer. Gastroenterology 135:518–528PubMedCrossRef Rhee SH, Im E, Pothoulakis C (2008) Toll-like receptor 5 engagement modulates tumor development and growth in a mouse xenograft model of human colon cancer. Gastroenterology 135:518–528PubMedCrossRef
33.
Zurück zum Zitat Song EJ, Kang MJ, Kim YS, Kim SM, Lee SE, Kim CH, Kim DJ, Park JH (2011) Flagellin promotes the proliferation of gastric cancer cells via the Toll-like receptor 5. Int J Mol Med 28:115–119PubMed Song EJ, Kang MJ, Kim YS, Kim SM, Lee SE, Kim CH, Kim DJ, Park JH (2011) Flagellin promotes the proliferation of gastric cancer cells via the Toll-like receptor 5. Int J Mol Med 28:115–119PubMed
34.
Zurück zum Zitat Yu L, Wang L, Chen S (2012) Exogenous or endogenous Toll-like receptor ligands: which is the MVP in tumorigenesis? Cell Mol Life Sci 69:935–949PubMedCrossRef Yu L, Wang L, Chen S (2012) Exogenous or endogenous Toll-like receptor ligands: which is the MVP in tumorigenesis? Cell Mol Life Sci 69:935–949PubMedCrossRef
Metadaten
Titel
Increased Toll-like receptor 5 expression indicates esophageal columnar dysplasia
verfasst von
Olli Helminen
Heikki Huhta
Heikki Takala
Petri P. Lehenkari
Juha Saarnio
Joonas H. Kauppila
Tuomo J. Karttunen
Publikationsdatum
01.01.2014
Verlag
Springer Berlin Heidelberg
Erschienen in
Virchows Archiv / Ausgabe 1/2014
Print ISSN: 0945-6317
Elektronische ISSN: 1432-2307
DOI
https://doi.org/10.1007/s00428-013-1505-2

Weitere Artikel der Ausgabe 1/2014

Virchows Archiv 1/2014 Zur Ausgabe

Neu im Fachgebiet Pathologie

Molekularpathologische Untersuchungen im Wandel der Zeit

Open Access Biomarker Leitthema

Um auch an kleinen Gewebeproben zuverlässige und reproduzierbare Ergebnisse zu gewährleisten ist eine strenge Qualitätskontrolle in jedem Schritt des Arbeitsablaufs erforderlich. Eine nicht ordnungsgemäße Prüfung oder Behandlung des …

Vergleichende Pathologie in der onkologischen Forschung

Pathologie Leitthema

Die vergleichende experimentelle Pathologie („comparative experimental pathology“) ist ein Fachbereich an der Schnittstelle von Human- und Veterinärmedizin. Sie widmet sich der vergleichenden Erforschung von Gemeinsamkeiten und Unterschieden von …

Gastrointestinale Stromatumoren

Open Access GIST CME-Artikel

Gastrointestinale Stromatumoren (GIST) stellen seit über 20 Jahren ein Paradigma für die zielgerichtete Therapie mit Tyrosinkinaseinhibitoren dar. Eine elementare Voraussetzung für eine mögliche neoadjuvante oder adjuvante Behandlung bei …

Personalisierte Medizin in der Onkologie

Aufgrund des erheblichen technologischen Fortschritts in der molekularen und genetischen Diagnostik sowie zunehmender Erkenntnisse über die molekulare Pathogenese von Krankheiten hat in den letzten zwei Jahrzehnten ein grundlegender …